Santen Pharmaceutical Co (4536) AI Stock Analysis

• Market Cap: ¥503.57B
• Dividend Yield: 2.44%
• Average Volume (3M): 1.17M
• Price to Earnings (P/E): 18.8
• Beta (1Y): 0.44
• Revenue Growth: -0.06%
• EPS Growth: 2.75%
• Country: JP
• Employees: 3,744
• Sector: Healthcare
• Sector Strength: 56
• Industry: Drug Manufacturers - General
• EPS (TTM): 78.31
• Shares Outstanding: 342,055,540
• 10 Day Avg. Volume: 775,490
• 30 Day Avg. Volume: 1,167,496
• PEG Ratio: 6.83
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥2,199.62
• Price Target Upside: 49.23% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Santen Pharmaceutical Co is performing well with strong financial metrics, including consistent revenue growth, improving profitability, and robust cash flows. The technical analysis suggests positive momentum, though caution is advised due to potential overbought indicators. Valuation metrics are reasonable with a fair P/E ratio and an attractive dividend yield. The absence of recent earnings call insights or impactful corporate events keeps the focus on these core elements.

Santen Pharmaceutical Co Business Overview & Revenue Model

Company Description

Santen Pharmaceutical Co., Ltd. is a specialized pharmaceutical company that primarily focuses on the research, development, manufacturing, and commercialization of ophthalmic products. Headquartered in Osaka, Japan, Santen is a leader in the field of eye care and offers a wide range of products, including prescription ophthalmic pharmaceuticals, over-the-counter (OTC) eye care products, and surgical devices. The company operates across multiple regions, including Japan, Asia, Europe, and the United States, and is dedicated to improving the quality of life for patients by providing innovative solutions for eye health.

How the Company Makes Money

Santen Pharmaceutical Co. generates revenue through the sale of its ophthalmic products, which are its core revenue stream. This includes prescription medications for conditions such as glaucoma, dry eye, and retinal disorders, as well as OTC eye care products. The company also earns income from its surgical device segment, which encompasses products used in ophthalmic surgeries. Santen's earnings are bolstered by its strong R&D capabilities, allowing it to develop new and effective treatments. Additionally, the company benefits from strategic partnerships and collaborations with other pharmaceutical companies and research institutions, enhancing its product offerings and market reach. Factors such as an aging global population and the increasing prevalence of eye diseases contribute to sustained demand for Santen's products.

Santen Pharmaceutical Co Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement		Total Revenue
301.96B	279.04B	266.26B	249.60B	241.56B
	Gross Profit
163.88B	166.09B	156.59B	151.38B	146.72B
	EBIT
38.54B	-3.09B	35.89B	12.92B	33.53B
	EBITDA
56.46B	14.30B	54.52B	30.01B	49.41B
	Net Income Common Stockholders
26.64B	-14.95B	27.22B	6.83B	23.62B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
94.96B	58.68B	84.31B	63.41B	91.88B
	Total Assets
435.70B	421.18B	459.98B	402.35B	408.77B
	Total Debt
35.16B	36.21B	32.93B	10.15B	12.33B
	Net Debt
-59.42B	-21.70B	-50.08B	-52.74B	-79.10B
	Total Liabilities
130.33B	127.88B	123.13B	95.30B	106.21B
	Stockholders Equity
306.06B	293.98B	337.49B	307.58B	302.87B
Cash Flow		Free Cash Flow
61.96B	12.56B	10.20B	15.00B	30.72B
	Operating Cash Flow
72.65B	37.15B	46.04B	38.81B	39.95B
	Investing Cash Flow
-6.14B	-26.78B	-35.17B	-53.35B	-5.17B
	Financing Cash Flow
-34.03B	-37.22B	5.56B	-16.68B	-12.73B

Santen Pharmaceutical Co Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1474.00
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4536, the sentiment is Positive. The current price of 1474 is above the 20-day moving average (MA) of 1402.05, above the 50-day MA of 1402.80, and below the 200-day MA of 1607.20, indicating a neutral trend. The MACD of 10.61 indicates Negative momentum. The RSI at 63.91 is Neutral, neither overbought nor oversold. The STOCH value of 92.94 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4536.

Santen Pharmaceutical Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4519	79 Outperform	$10.34T	26.70	22.80%	1.02%	17.96%	25.65%
4503	77 Outperform	¥2.63T	51.43	3.22%	4.87%	19.25%	294.48%
4536	76 Outperform	¥503.57B	18.82	9.17%	2.44%	-0.06%	2.75%
4528	75 Outperform	¥782.90B	10.59	9.06%	4.16%	-2.16%	-40.39%
4502	68 Neutral	$7.00T	33.49	2.87%	4.25%	9.83%	15.49%
4506	54 Neutral	$373.85B	―	-68.59%	―	12.84%	-1.34%
Sector *	52 Neutral	$5.35B	3.81	-42.57%	2.86%	17.10%	1.33%

Santen Pharmaceutical Co Corporate Events

Santen Pharmaceutical Co. Revises Year-End Dividend Forecast

Santen Pharmaceutical Co., Ltd. announced a revision of its year-end dividend forecast following a Board of Directors meeting. The company increased its fiscal year-end dividend forecast from 17 yen to 19 yen per share, resulting in a total annual dividend of 36 yen per share for the year ending March 31, 2025. This change reflects Santen’s commitment to returning profits to shareholders, aligned with its progressive dividend policy and medium to long-term earnings prospects.

Santen Pharmaceutical to Cancel 5 Million Treasury Shares

Santen Pharmaceutical Co., Ltd. announced the cancellation of 5 million treasury shares, representing 1.4% of its outstanding shares, as part of a decision made by its Board of Directors. This move, scheduled for February 28, 2025, is likely to impact the company’s share structure and could reflect a strategic effort to optimize its capital allocation, potentially benefiting shareholders by improving return on equity.

Santen Pharmaceutical Reports Financial Results and Strategic Initiatives

Santen Pharmaceutical reported its consolidated financial results for the nine months ending December 31, 2024, showing slight revenue stability but a decrease in core operating and net profits. Despite this, the company forecasts a significant improvement in operating and net profits for the year ending March 31, 2025, indicating strategic adjustments, including share repurchases and cancellations, to enhance shareholder value.